How Much Does Dayvigo (Lemborexant) Cost in North Carolina in 2026?

Dayvigo List Price vs. Real-World Cost in North Carolina

The sticker price on a Dayvigo prescription rarely reflects what patients actually hand over at the pharmacy counter. Eisai, the manufacturer, sets the wholesale acquisition cost at $320 for a 30-day supply of either the 5 mg or 10 mg tablet [1]. Across North Carolina retail pharmacies in 2026, the average cash price without insurance runs closer to $85 per month when patients use discount pricing tools.

That gap between $320 and $85 exists because of negotiated rebates, pharmacy benefit manager contracts, and discount card programs that have expanded since the drug's FDA approval in December 2019 [2]. The FDA approved lemborexant based on the SUNRISE-1 trial (N=1,006), which demonstrated statistically significant improvements in sleep onset and sleep maintenance versus placebo in adults aged 55 and older [3]. Patients receiving lemborexant 10 mg fell asleep 10.5 minutes faster and spent 20.1 fewer minutes awake after sleep onset compared to placebo at one month.

Price variation between NC pharmacies is real. A CVS in Charlotte may charge a different cash rate than an independent pharmacy in Asheville. Checking multiple pharmacy quotes before filling is worth the 10 minutes it takes. GoodRx, RxSaver, and the Eisai Co-Pay Savings Program all produce different price points depending on your zip code and the specific pharmacy's contracted rates [1].

North Carolina Medicaid and Dayvigo Coverage

NC Medicaid does not cover Dayvigo for insomnia as of 2026. The North Carolina Division of Health Benefits maintains a preferred drug list that excludes lemborexant from the insomnia category. This means Medicaid beneficiaries prescribed Dayvigo will face a claim denial at the point of sale.

The reasoning is straightforward: NC Medicaid's preferred alternatives for insomnia include generic trazodone, generic zolpidem, and generic suvorexant (which became available after Belsomra's patent exclusivity changes). The American Academy of Sleep Medicine's 2023 clinical practice guideline recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, with pharmacotherapy reserved for patients who do not respond adequately [4]. Among pharmacotherapy options, the guideline gives a conditional recommendation for dual orexin receptor antagonists including lemborexant and suvorexant.

For Medicaid patients who have tried and failed preferred agents, a physician can submit a prior authorization exception request. Approval rates for these exceptions remain low. Dr. Andrew Krystal, a sleep medicine researcher at UCSF, has noted that "the orexin receptor antagonists represent a mechanistically distinct approach to insomnia treatment that may benefit patients who have not responded to GABA-modulating agents" [5]. That clinical rationale can support an appeal, but NC Medicaid denials for non-preferred branded sleep medications are common.

If you are on Medicaid and your provider recommends Dayvigo specifically, ask about the Eisai patient assistance program, which may cover the full cost for qualifying low-income patients regardless of insurance status [1].

Commercial Insurance Coverage for Dayvigo in NC

Most major commercial insurers operating in North Carolina place Dayvigo on a specialty or non-preferred brand tier with prior authorization requirements. Blue Cross Blue Shield of North Carolina, the state's largest insurer, typically requires documentation that the patient has tried at least one preferred sleep agent before approving Dayvigo coverage.

Cigna, Aetna, and UnitedHealthcare plans sold through the NC ACA marketplace follow similar step-therapy protocols. The copay with commercial insurance after prior authorization approval generally falls between $30 and $75 per month, depending on the plan's tier structure [1].

A 2021 analysis published in the Journal of Managed Care & Specialty Pharmacy found that prior authorization for DORAs resulted in a 34% initial denial rate across commercial payers, though 62% of appeals were ultimately approved when supporting documentation included a failed trial of at least one alternative agent [6]. Getting prior auth approved on the first attempt requires your prescriber to document previous medication trials, their durations, and reasons for discontinuation.

Step therapy typically means trying generic zolpidem or trazodone for 30 to 90 days before the insurer will consider covering Dayvigo. Some NC plans also accept a failed trial of suvorexant. Your prescriber's office handles the prior authorization paperwork, but you can accelerate the process by confirming which specific agents your plan considers "preferred" before your appointment.

The Eisai Savings Card and How It Works in NC

Eisai offers a co-pay savings program that can reduce out-of-pocket costs to as little as $0 per month for commercially insured patients. The card is not valid for patients enrolled in any federal or state government healthcare program, including Medicare Part D, Medicaid, TRICARE, or VA benefits [1].

Eligibility requirements are specific. You must have commercial insurance that covers at least part of the Dayvigo prescription. The savings card then covers the remaining copay up to a set annual maximum (typically $3,600 per year as of 2026). The card resets annually.

Activation is simple: visit the Eisai Dayvigo savings program website, complete the enrollment form, and present the card at your NC pharmacy alongside your insurance card. The pharmacy processes the insurance claim first, then applies the savings card to whatever balance remains [1].

Patients without any insurance do not qualify for the co-pay card but may qualify for Eisai's separate Patient Assistance Program (PAP), which provides Dayvigo at no cost to patients meeting income thresholds. Household income must generally fall below 400% of the federal poverty level. The application requires income verification documents and a signed prescription from your provider.

Compounded Lemborexant in North Carolina: Legal Status and Access

Compounded lemborexant is available in North Carolina through licensed 503A compounding pharmacies. This is legal under both federal law (section 503A of the Federal Food, Drug, and Cosmetic Act) and North Carolina Board of Pharmacy regulations, provided the compounding pharmacy holds a valid NC license and fills prescriptions based on individual patient prescriptions from a licensed prescriber [7].

A 503A pharmacy compounds medications on a patient-specific basis. The prescriber writes a prescription for lemborexant, and the compounding pharmacy prepares the medication from bulk pharmaceutical-grade ingredients. This differs from a 503B outsourcing facility, which can compound without patient-specific prescriptions but must register with the FDA and follow current good manufacturing practices [7].

Compounded versions typically cost significantly less than branded Dayvigo. Some NC compounding pharmacies offer lemborexant preparations for minimal out-of-pocket cost, particularly when the pharmacy operates on a membership or subscription model.

There are trade-offs. Compounded medications do not undergo the same FDA review process as commercially manufactured drugs. The SUNRISE-1 and SUNRISE-2 trials that established lemborexant's efficacy used the commercially manufactured Eisai product [3][8]. Bioavailability and consistency between compounded preparations and the branded tablet have not been independently validated in published studies. The FDA has stated that "compounded drugs are not FDA-approved" and that patients should "be aware that compounded drugs carry additional risks" [7].

Discuss the compounded option with your prescriber. If cost is the primary barrier to treatment, a compounded preparation may be appropriate, but both you and your provider should weigh the trade-off between cost savings and product standardization.

Telehealth Prescribing of Dayvigo in North Carolina

North Carolina permits telehealth prescribing of Dayvigo. The NC Medical Board allows prescribers to establish a valid patient-provider relationship via synchronous audio-video telehealth visits, after which they can prescribe Schedule IV controlled substances including lemborexant [9].

Lemborexant is classified as Schedule IV under the Controlled Substances Act because of its low abuse potential relative to Schedule III agents [2]. The DEA's post-pandemic telehealth prescribing flexibilities, extended through 2025 and now formalized in updated regulations for 2026, allow initial prescriptions of Schedule III-V substances via telehealth without a prior in-person visit in most circumstances [9].

Several telehealth platforms operate in North Carolina and include Dayvigo in their formularies. When choosing a telehealth provider, verify three things: the prescriber is licensed in North Carolina, the platform can send electronic prescriptions to your preferred NC pharmacy, and the visit fee fits your budget (typically $50 to $150 for an initial sleep consultation).

A telehealth visit for insomnia should include a sleep history, screening for obstructive sleep apnea and other comorbid conditions, discussion of CBT-I as first-line treatment per AASM guidelines [4], and a medication plan if pharmacotherapy is indicated. The SUNRISE-2 trial (N=949) demonstrated that lemborexant 5 mg and 10 mg maintained efficacy over 12 months of nightly use, with no evidence of rebound insomnia upon discontinuation at 12 months [8]. This long-term safety profile supports ongoing telehealth management with periodic follow-up visits.

How to Get the Lowest Price on Dayvigo in North Carolina

The cheapest path depends on your insurance situation. Here is a decision framework based on coverage type.

Commercially insured with Dayvigo coverage: Use the Eisai co-pay savings card to reduce your copay toward $0. Confirm your plan covers Dayvigo (even at a non-preferred tier) and apply the card at the pharmacy [1].

Commercially insured without Dayvigo coverage: Ask your prescriber to submit a prior authorization. Document any failed trials of generic sleep medications. If denied, appeal with clinical notes. While waiting, use a discount card at a cash-pay pharmacy for approximately $85 per month [1].

Uninsured: Apply for Eisai's Patient Assistance Program if your income qualifies. If not eligible, compare cash prices at NC pharmacies using GoodRx or RxSaver. Consider a licensed 503A compounding pharmacy for lower-cost compounded lemborexant [7].

Medicare Part D: Dayvigo sits on most Part D formularies at a Tier 3 or Tier 4 level. Copays vary by plan but often run $40 to $90 per month after the deductible. The Eisai savings card cannot be used with Medicare. Patients reaching the coverage gap may benefit from Part D's manufacturer discount program, which covers 70% of the brand cost in the gap phase [10].

NC Medicaid: Coverage is not available for insomnia. Explore the Eisai PAP or compounded alternatives. Your prescriber may also consider suvorexant (generic) if it is covered on your Medicaid formulary.

Dr. Phyllis Zee, chief of sleep medicine at Northwestern University Feinberg School of Medicine, has emphasized that "cost should not be the reason a patient with chronic insomnia goes untreated, given the cardiovascular, metabolic, and psychiatric consequences of persistent sleep disruption" [5]. If Dayvigo's price is a barrier, work with your prescriber to find an alternative pathway to treatment.

Comparing Dayvigo to Other Insomnia Medications Available in NC

Lemborexant is not the only option, and understanding comparative costs helps frame the decision. Generic zolpidem (Ambien) costs $5 to $15 per month at most NC pharmacies. Generic trazodone runs $4 to $10 per month. These are the agents NC Medicaid and most commercial step-therapy protocols require patients to try first.

Suvorexant (Belsomra), the other branded DORA, carries a list price of approximately $400 per month, though generic suvorexant has entered the market and reduced costs substantially [2]. Both lemborexant and suvorexant work by blocking orexin receptors, which promote wakefulness, rather than enhancing GABA signaling like benzodiazepines and Z-drugs [3].

The clinical distinction matters. A pooled analysis of the SUNRISE trials found that lemborexant 10 mg reduced wake after sleep onset (WASO) by 28.5 minutes versus placebo, compared to 22.7 minutes for suvorexant 20 mg in its own registration trials [3][11]. Head-to-head data are limited, but the SUNRISE-1 trial did include a suvorexant 20 mg arm and found that lemborexant 10 mg produced numerically greater improvements in sleep efficiency (difference in sleep efficiency versus placebo: 4.8% for lemborexant 10 mg vs. 3.4% for suvorexant 20 mg, P<0.05) [3].

For patients who cannot tolerate or have not responded to GABA-modulating agents, DORAs represent a mechanistically different approach. The choice between lemborexant and suvorexant often comes down to formulary placement and cost after insurance. In North Carolina, whichever DORA your plan prefers will be the less expensive option.